0x

guest@0xbase ~$ read-only mode. Posting requires EU location.

← back to intelligence feed

Study Details NCT02374385: Phase I Trial to Assess the Safety of the VSV ZEBOV Vaccine (clinicaltrials.gov)

· 17d ago · Report · Spotlight this ·
0xBASE INTEL BRIEF
  • Phase I trial of Ervebo (VSV-ZEBOV) safety
  • Randomized, placebo-controlled, healthy adults
  • Outcomes: adverse events, immunogenicity

"This clinical trial (NCT02374385) assesses the safety of the Ervebo (VSV ZEBOV) Ebola vaccine. The Phase I study provides foundational data on tolerability and immunogenicity, critical for vaccine development and regulatory approval."

#vaccine safety #Phase I trial #VSV-ZEBOV
Read article on clinicaltrials.gov → More from clinicaltrials.gov

Discussion Matrix

0 segments

no comments yet.